New options in the treatment of non-small cell lung cancer

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Docetaxel 100%
• Response Rate 42%
• Duration of Response 28%
• Vinorelbine 28%
• Quality of Life 14%
• Phase II Study 14%
• Median Survival 14%
• Agent Behavior 14%
• Carboplatin 14%
• Active Agent 14%
• Phase II Trial 14%
• Cisplatin 14%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 14%
• Phase I Trial 14%
• Lung Cancer Symptoms 14%
• Randomized Phase III Trial 14%
• Ifosfamide 14%
• First-line Regimen 14%
• Safety Self-efficacy 14%
• Platinum-based Chemotherapy 14%
• Gemcitabine 14%
• Taxanes 14%
• Life Safety 14%
• Second-line Treatment 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Docetaxel 100%
• Vinorelbine 28%
• Carboplatin 14%
• Chemotherapy 14%
• Lung Cancer 14%
• Gemcitabine 14%
• Cisplatin 14%
• Phase I Trials 14%
• Ifosfamide 14%